Modality
Multispecific
MOA
MALT1i
Target
DLL3
Pathway
Apoptosis
Parkinson'sHSMM
Development Pipeline
Preclinical
Jan 2024
→ May 2026
PreclinicalCurrent
NCT04866654
363 pts·MM
2024-01→2026-05·Terminated
363 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-05-061mo awayInterim· MM
2026-07-194mo awayBTD· HS
Trial Timeline
2024Q2Q3Q42025Q2Q3Q42026Q2Q3
Preclinical
Termina…
Catalysts
Interim
2026-05-06 · 1mo away
MM
BTD
2026-07-19 · 4mo away
HS
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04866654 | Preclinical | MM | Terminated | 363 | eGFR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-7809 | Pfizer | Phase 1 | DLL3 | |
| JNJ-2735 | Johnson & Johnson | Phase 2/3 | Cl18.2 | |
| Riboinavolisib | Johnson & Johnson | Phase 2/3 | GLP-1R | |
| RHH-974 | Roche | Preclinical | JAK1 | |
| NVS-3297 | Novartis | Preclinical | CDK2 | |
| ABB-8985 | AbbVie | Phase 2 | CD20 | |
| Pexarelsin | AstraZeneca | Phase 1 | DLL3 | |
| Zorivorutinib | Bristol-Myers Squibb | Approved | DLL3 | |
| Zenonesiran | GSK | Preclinical | DLL3 | |
| AMG-7379 | Amgen | Preclinical | DLL3 |